Event Brief
UPDATED Apr 6, 2026 at 12:09 PM ET
Apr 6, 2026 at 12:03 AM ET
Neurocrine nears $2.5bn deal for obesity treatment
By The BriefBrief
Neurocrine Biosciences is close to acquiring Soleno Therapeutics, which developed a drug for Prader-Willi syndrome.
WHO: Neurocrine Biosciences
WHAT: Acquisition of Soleno Therapeutics
WHEN: Apr 5, 2026 at 10:47 PM ET
WHERE: USA
WHY: Part of a strategic move to enhance their product portfolio in obesity treatment.
How this brief is built: The BriefBrief correlates multiple sources into one evolving event brief, updated as new facts emerge.
Amazon faces months of repairs after drone strikes
Amazon
May 1, 2026 at 3:23 PM ET
Minnesota bans fake AI nudes; app makers face $500K
Minnesota
May 1, 2026 at 3:23 PM ET
Page 21432 of 21432
Same format. Every time.
Continue reading — sign in or create a free account with
